Form D · Biotechnology

Calyx Bio-Ventures Inc.

Vancouver, A1 · CIK 0001562755

Offering snapshot reported Nov 23, 2012 · SEC filing

Reported sold
$60K
Offering amount: $2.51M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 9, 2012
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 23, 2012Initial$59,965No comparison1SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired, Other
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-187395
The additional $2,447,731 may be received upon exercise of share purchase warrants sold both inside and outside the U.S. U.S. dollar amounts are based on the Bank of Canada noon rate of exchange reported on November 9, 2012, which was Cdn$1.0006=US$1.00.
Each unit is comprised of one common share and one half of one share purchase warrant. Each whole warrant is exercisable for one common share at an exercise price of Cdn$0.60 per share for a period of 12 months.

Source: Form D, filed Nov 23, 2012. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
David T. Howard Director
Douglas Johnstone Executive
Louis Lacasse Director
Stuart Mac Gregor Director
William Hugh Notman Director, Executive
Richard Whittall Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
450 400 Burrard Street
Vancouver, A1, V6C 3A6